Northwest Bio says DCVax-L hospital exemption program under way in Germany

15 October 2014

US biotech firm Northwest Biotherapeutics (Nasdaq: NWBO), which is developing DCVax personalized immune therapies for solid tumor cancers, says that the DCVax-L hospital exemption program that was approved by the German regulatory authority earlier this year is now under way.

The first patient with glioblastoma multiforme (GBM) brain cancer has begun the treatment process, additional patients are being assessed and a waiting list has been established. The news pushed Norwest Bio’s shares 3.4% higher to $4.07 in mid-morning trading on Tuesday.

NW Bio's DCVax-L is the first immune therapy to be granted a hospital exemption approval under the German Drug Law. The scope of this includes all glioma brain cancers, both GBM (the most severe grade) and lower grade (less malignant) gliomas, and includes both newly diagnosed (ie, early stage) as well as recurrent (ie, late stage) patients. The patients must receive treatment in Germany, but may be either from Germany or from abroad.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK